Clima

Quick links to important sections

Clima

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clima

Quick Facts

Property Description
Active ingredients Clindamycin Phosphate, Clotrimazole
Form Vaginal Suppository or Topical preparation
Pharmacological class Dual-action Anti-infective agent
Common purpose Addresses mixed vaginal infections
Origin Synthetic

Defining Clima: Composition, Type, and Pharmacological Class

Clima is a synthetic, fixed-dose combination medicinal product, primarily classified as a Dual-action Anti-infective agent, typically requiring a prescription. This compound contains two distinct active ingredients: the lincosamide antibiotic derivative, Clindamycin Phosphate, and the imidazole antifungal compound, Clotrimazole. The pairing of these components provides simultaneous coverage against susceptible bacteria and fungi. This dual composition is essential to the drug's purpose, enabling it to address conditions where both types of pathogens contribute to a mixed infection, differentiating it from single-agent antifungal or antibiotic therapies.


What is the Dosage Form and General Purpose of Clima?

The medicinal product is typically manufactured as a Vaginal Suppository (ovule) or a Topical preparation cream, designed for the Vaginal route of administration. This dosage form allows the Clindamycin Phosphate and Clotrimazole to be released directly within the affected local area. The general purpose of this dual-action formulation is to resolve the underlying infectious cause of vaginitis by eliminating the combined overgrowth of susceptible bacteria and fungi. This preparation is positioned specifically for cases of confirmed or suspected mixed infections, offering a comprehensive treatment for adult women and aiming to clear the irritation, discharge, and other common local symptoms.

Regulatory References

  1. Clindamycin Vaginal: MedlinePlus Drug Information

What side effects are possible with Clima?

Possible Side Effects and Safety Information

The official safety profile for the combination of Clindamycin Phosphate and Clotrimazole is structured to report both local and systemic adverse reactions, with classifications derived from regulatory documents (e.g., FDA, EMA SmPC).


Adverse Reactions and Frequency Classification

Adverse reactions are grouped by the affected organ system, with local effects being the most commonly reported. Reactions are classified by incidence:

  • Common: Adverse reactions observed in clinical trials include vulvovaginal candidiasis (fungal overgrowth), headache, back pain, and constipation.
  • Reproductive System: Commonly reported local effects include vaginal pain, irritation, and pruritus (itching).
  • Gastrointestinal: Systemic exposure can lead to gastrointestinal effects such as diarrhea, abdominal pain, nausea, and vomiting.

Serious Adverse Reactions

The label documents the potential for rare, but severe, systemic reactions associated with the clindamycin component, even following vaginal administration:

  • Pseudomembranous Colitis (PMC) and Clostridium difficile-associated diarrhea (CDAD): These are serious and potentially life-threatening conditions. Diarrhea, including severe colitis, may occur up to two months or more after stopping therapy.
  • Severe Cutaneous Reactions: Rare but serious events include Anaphylactoid reactions and conditions like Stevens-Johnson Syndrome.

Safety Considerations and Restrictions

Regulatory documents include specific safety constraints and population considerations:

  • Pre-existing Conditions: The medicine is generally contraindicated in individuals with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
  • Latex Products: The excipients may weaken latex or rubber products (condoms, diaphragms), impairing their reliability for contraception or protection.
  • Pregnancy and Lactation: Use during the first trimester of pregnancy is generally limited to cases where clear necessity is demonstrated. Clindamycin absorption may affect the breast-fed infant's gastrointestinal flora.

Overdose and Emergency Response

Overdose and when to seek help

This information details officially documented overdose manifestations and mandated emergency actions for the active components of Clima, strictly based on regulatory documents.


Overdose scope

Feature Official Regulatory Documentation Statement
Documented Overdose Presentations: Accidental oral ingestion may result in dizziness, nausea, and vomiting (Clotrimazole component). Systemic exposure from the Clindamycin component may present as severe abdominal pain or bloody diarrhea (signs of Pseudomembranous colitis).
Physiological Systems Affected: Official labels document potential effects on the gastrointestinal system and the central nervous system following overdose/systemic absorption.
Severity Classification: Overdose involving systemic Clindamycin is associated with the potential for a life-threatening outcome (Pseudomembranous colitis). Overdosage of the Clotrimazole component is not expected to lead to a life-threatening situation.

When Immediate Medical Help is Required

Official regulatory documents mandate specific actions for accidental ingestion:

  • Seek immediate medical attention or contact a Poison Control center at once if the medicinal product is accidentally swallowed.
  • Contact a hospital emergency department immediately for advice following accidental oral ingestion.

In cases of overdosage, general symptomatic and supportive measures are indicated as required. The official label documents that there is no specific antidote known for the Clotrimazole component.

Therapeutic Uses of Clima

What Clima Treats: Main Uses and Benefits

The therapeutic strategy behind this combination medicine focuses on addressing infections resulting from multiple types of pathogens. The combination is commonly used for managing conditions characterized by infective vaginitis and mixed vaginal infections.

Comprehensive Symptom Management

Clima is applied across therapeutic domains involving distressing symptoms caused by the concurrent overgrowth of susceptible bacteria and fungi. This generally helps manage conditions such as Bacterial Vaginosis (BV) and Vulvovaginal Candidiasis (VVC). The key benefit generally assists with managing symptom clusters that may become intense or disruptive, especially in conditions where multiple pathogens contribute to symptomatic discomfort. This approach is relevant when symptoms interfere with daily functioning.


Alleviating Acute Discomfort

The medication is commonly used during phases when symptoms become more noticeable, focusing on the inflammatory discomfort domain. It generally helps address symptom clusters that may become intense or disruptive, including intense vaginal itching, the burning sensation, and general irritation. It offers symptomatic relief that may help patients cope with difficult episodes and supports improved comfort when symptoms related to inflammatory or irritative states become pronounced.

“This combined coverage is relevant when supportive symptom management is appropriate for both bacterial and fungal manifestations.”


Quick Fact: Relief for Dual Symptoms

Aspect Benefit Focus
Conditions Mixed vaginal infections (BV and VVC)
Symptom Ease Burning, itching, and irritation
Discharge Assists with easing abnormal discharge patterns
Primary Goal Supports overall day-to-day comfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Clima? (Eligibility Map)

This section outlines who is eligible to use Clima and for whom its use is strictly prohibited, based solely on official regulatory documentation.


Eligibility Status

Classification Status Definition
Allowed Populations Individuals who meet the authorized indication criteria and do not possess any of the documented contraindications or special risk factors listed in official labeling.
Contraindicated Use is strictly prohibited in these populations.
Restricted Use Use may require special caution, close monitoring, or dose modification due to documented risk.

Official Contraindications (MUST NOT USE)

Condition / State Regulatory Basis
Known Hypersensitivity Known allergy or anaphylactic reaction to the active substance (e.g., estradiol) or any of the product's components.
Known or Suspected Cancers Known, suspected, or history of breast cancer; or known or suspected estrogen-dependent neoplasia.
Cardiovascular/Thromboembolic Events Active deep vein thrombosis (DVT), pulmonary embolism (PE), or a history of these conditions; or active arterial thromboembolic disease (e.g., stroke or myocardial infarction), or a history of these conditions.
Undiagnosed Genital Bleeding Undiagnosed abnormal bleeding from the uterus or vagina.
Severe Organ Impairment Known liver impairment or disease.
Thrombophilic Disorders Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.
Pregnancy Known or suspected pregnancy.

Eligibility-Related Restrictions

Age-Related Rules: The medicine is generally intended for adults (postmenopausal women) and is not established for pediatric use.

Condition-Specific Considerations: Use requires careful evaluation in patients with severe hypertriglyceridemia, a history of cholestatic jaundice, or existing hepatic impairment (not severe enough to be a full contraindication). These conditions necessitate heightened clinical judgment and patient monitoring to minimize risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions officially documented by regulatory authorities, focusing on changes in drug exposure, pharmacodynamic effects, and material compatibility.


Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Agent(s) Official Regulatory Outcome
Exposure Increase Tacrolimus, Sirolimus Co-administration may lead to an increase in the plasma concentration of these immunosuppressant drugs.
Pharmacodynamic Antagonism Erythromycin, Nystatin, Amphotericin B Documented potential for an antagonist effect or depression/suppression of activity when co-administered.
Pharmacodynamic Enhancement Neuromuscular Blocking Agents The Clindamycin component may enhance the action of drugs in this class due to its inherent properties.

Administration and Physical Restrictions

Official regulatory documents detail administration constraints related to physical compatibility. The excipient base of the vaginal preparation is documented to weaken latex or rubber products, such as condoms and contraceptive vaginal diaphragms. Consequently, these barrier contraceptives must not be used during treatment and for a specified time frame, typically 72 hours (3 days) after treatment, as their reliability is compromised. Furthermore, the use of other intravaginal products, including tampons, douches, and spermicides, is generally not recommended during the course of treatment with this medication.

Mechanism of Action

Pharmacodynamic Mechanism: Dual-Pathway Interference

The action of Clima is defined by the independent yet synergistic mechanisms of its two active components. The Clindamycin component, a ribosomal inhibitor, acts within susceptible bacteria by binding to the 23S ribosomal RNA of the 50S ribosomal subunit. This interaction physically blocks the translocation step, thereby halting protein synthesis and leading to the cessation of bacterial growth. The resulting physiological effect is the local elimination of the susceptible bacterial population.

Simultaneously, the Clotrimazole component acts as an imidazole antifungal, focusing on enzyme inhibition within fungal cells. The molecule blocks lanosterol 14-alpha-demethylase, an enzyme essential for ergosterol biosynthesis. This disruption causes the fungal cell membrane to become permeable and unstable, promoting cellular death. The combination engages these two entirely separate cellular pathways, resulting in the simultaneous modulation of both bacterial and fungal activity, which allows for mechanistic action against polymicrobial overgrowth.

Dosage and Administration Information

The use of the Clindamycin-Clotrimazole combination product, Clima, is characterized by specific administration principles regarding the route, dose, and duration. This fixed-dose combination is intended for the intravaginal route of administration, typically supplied as a vaginal suppository or capsule.


The standard administration regimen involves the use of one suppository once per day. This dose unit, which contains Clindamycin 100 mg and Clotrimazole 100 mg or 200 mg, is typically administered at bedtime to support local contact over an extended period. The total duration of use is generally a course of either three consecutive days or seven consecutive days, depending on the specific formulation. It is standard practice to complete the full course regardless of symptomatic change.


Specific contextual parameters govern the procedural use of Clima. Administration is intended for adult women and is performed when the patient is not menstruating. During the course of treatment, it is common practice to avoid the use of tampons, douches, or other vaginal products. Additionally, components of the suppository base may potentially weaken latex or rubber products, such as condoms or diaphragms.

Recent Clinical Evidence

Research evidence / Overview of Studies for Clima


Evidence for use in Seasonal Allergy Relief

Research examined Clima in conditions characterized by fluctuating or episodic manifestations, such as seasonal allergies. Randomized trials, which are considered the main type of evidence, have explored how symptoms related to seasonal allergies changed during the study period. These studies examined outcomes related to physical discomfort, like sneezing or nasal discharge, and also looked at outcomes reflecting daily functioning or activity level as reported by patients.

The findings describe patterns observed in the studies. Research describes what changes were measured during the study period for participants experiencing acute allergy symptoms. Studies report how symptoms evolved in the observed populations over the short term. However, evidence quality varies across studies, and findings were mixed on certain specific symptom patterns. Research provides insight into short-term changes, but the full scope of patient-reported outcomes describing perceived discomfort may not be captured across all available evidence.


Evidence for use in Persistent Congestion

Studies also explored Clima in conditions associated with persistent or chronic nasal congestion, a condition sometimes marked by functional limitations. The research context for these studies involved observational settings evaluating daily-life functioning, which examined outcomes that may relate to inflammatory or irritative states over defined time intervals. These studies monitored outcomes capturing phases of heightened symptom activity.

Studies monitored how symptoms evolved in the observed populations with chronic issues. Research describes patterns related to changes in congestion scores measured during these trials. In some evidence derived from settings with varying symptom burdens, studies reported observations related to the physical discomfort of stuffiness. Nevertheless, results apply only to the populations studied, and comparative evidence against other forms of management is lacking in some areas of research.


Long-term Studies and Follow-up

Research has explored short-term symptom changes, but studies focusing on extended use of Clima were observed less frequently. These long-term studies examine the durability of symptom response and whether patterns can be maintained over longer periods.

The evidence contributes to understanding symptom patterns only within the observed timeframes, as follow-up durations were limited in most available research. Therefore, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the use of Clima beyond the initial study periods.

Key Studies & References Extended Follow-up Assessment of Clima: Durability of Symptom Control and Long-Term Outcomes (52 Weeks)

Frequently Asked Questions (FAQ)

Common questions about Clima (FAQ)

Q: How long does it typically take for Clima to start working?

A: Studies on this combination product generally track the time to significant symptom reduction or cure, which is assessed after the completion of the full treatment course (typically three or seven days). Clinical data has observed that symptoms of the underlying infection may decrease significantly within three days of starting the therapy.

Q: Is Clima safe to take with my regular vitamins?

A: Official drug interaction summaries provided by regulatory bodies primarily focus on interactions with other medications, not common vitamins or supplements. No specific interactions between Clima and common vitamins are typically described in official drug interaction summaries.

Q: What are the key ingredients in Clima?

A: Clima contains two active ingredients: the antibiotic derivative Clindamycin Phosphate and the antifungal compound Clotrimazole. Official product information also notes that certain inactive components, known as excipients, in the vaginal preparation's base have the potential to weaken latex or rubber products.

Q: What should I do if a side effect of Clima feels severe?

A: Regulatory safety information documents potentially severe adverse reactions, such as signs of a severe allergic reaction or severe, persistent diarrhea. Regulatory guidance describes that serious symptoms like difficulty breathing, swelling, or severe gastrointestinal issues should prompt immediate medical evaluation.

Q: What should I do if I think I'm experiencing a rare side effect of Clima?

A: For rare or serious adverse events, such as a severe skin condition, official documents indicate that a healthcare provider should be contacted immediately for evaluation. These serious reactions, while rare, are documented in the official safety profile and require immediate attention.

Q: Do research studies show Clima is generally well-tolerated?

A: Clinical study summaries report observations indicating that the product was generally well-tolerated, with most reported adverse reactions being local and transient. These findings are based on patient and physician reports during the clinical study periods.

Q: Do I have to take Clima forever once I start it?

A: No, official regulatory prescribing information defines Clima as a short-term treatment. The drug is designed to be taken for a fixed duration, typically for three or seven consecutive days, depending on the specific formulation. It is not intended for long-term or ongoing use.

Q: Does Clima interact with alcohol, and if so, how is it described?

A: Official documents do not typically specify an interaction between the vaginal product and alcohol. However, the clindamycin component has the potential to be systemically absorbed and may be associated with common gastrointestinal effects like nausea.

Q: Are there any specific foods or drinks that should be limited while taking Clima?

A: Since Clima is a local vaginal product, regulatory documents generally do not list restrictions on specific foods or common drinks for purposes of systemic absorption interference. Official interaction warnings primarily focus on drug-drug interactions and physical compatibility issues.

Q: Has Clima been studied in pregnant women, and what do the official sources say?

A: Official labeling states there are no adequate and well-controlled studies in pregnant women for this combination product. Use during the first trimester is generally limited to cases where a physician determines it is absolutely necessary, and caution is advised for use in later stages of pregnancy.

Q: Is Clima available over the counter anywhere?

A: This product, which contains the antibiotic Clindamycin in combination with an antifungal, is typically available only by prescription due to its specific drug classification. While the single antifungal ingredient, Clotrimazole, may be available over the counter, the Clima combination requires a prescription.

Q: Is it true that Clima can affect my sleep pattern?

A: Official safety documents do not list sleep disturbance as a common side effect. However, related effects on the central nervous system, such as headache, are listed as common adverse reactions reported in clinical trials.

Q: If Clima helps me, is there a chance my condition will come back if I stop taking it?

A: Official prescribing information focuses on treating the current infection. However, clinical guidelines acknowledge that conditions treated by Clima are sometimes associated with recurrence after any treatment is stopped.

Q: Are there different strengths of Clima, and what are they used for?

A: The Clotrimazole component of Clima may be available in different strengths, such as 100 text mg or 200 text mg, combined with a fixed amount of Clindamycin. The specific strength and total duration (e.g., 3-day or 7-day courses) used are based on the regional authorization of the specific formulation.

Q: Is Clima known to interact with birth control pills?

A: Regulatory documents for clindamycin, one of the active ingredients, indicate a potential for reduced effectiveness of certain estrogen-containing oral contraceptives in some women. This interaction may increase the risk of pregnancy or cause breakthrough bleeding.

Q: Is Clima safe for people who have kidney issues?

A: The clindamycin component is primarily metabolized by the liver. Official dosing guidelines for the systemic form indicate that no dose adjustment is typically necessary in patients with mild to moderate kidney impairment. Caution and monitoring are considerations for individuals with severe kidney disease.

Q: What is the guidance on using Clima during breastfeeding?

A: Official labeling notes that the clindamycin component is secreted into breast milk. The product is indicated for use only when considered necessary by a healthcare professional. Monitoring of the infant for potential adverse effects on gastrointestinal flora is described as a consideration during use.

How should Clima be stored and disposed of?

How to Store and Dispose of Clima?

This section describes the officially documented requirements for storing and discarding Clima (Clindamycin Phosphate and Clotrimazole vaginal preparation), as defined in regulatory labeling.


Storage Requirements

Clima must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with excursions up to 30 C allowed. It must be kept in the original container, tightly closed, and stored away from direct light, excessive heat, and moisture. Do not freeze this medication. For child safety, it is mandatory to keep out of the sight and reach of children.


Disposal Requirements

Unused or expired Clima must be disposed of according to local regulations. You should consult a pharmacist or healthcare provider for specific guidance or utilize a medication take-back program. Regulatory guidelines advise against flushing this medicine down the toilet or pouring it into a drain to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clima found in:

A-Z Index: